Clinical Trials Sponsored by Jiangsu Cancer Institute & Hospital

Total 4013 results

Peking University Cancer Hospital & Institute

Not yet recruiting

Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer (PKUCH-R09)

Rectal Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

Fallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

PD-L1 Specific [68Ga]-Nb-1 Nanobody Probe for PET Imaging in Solid Tumors

Solid Tumor

China
Shandong Cancer Hospital and Institute

Recruiting

First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC

Intrahepatic Cholangiocarcinoma

China
Shandong Cancer Hospital and Institute

Recruiting

Sintilimab Combined With Fruquintinib/Regorafenib ± Radiotherapy for Third-line Treatment of Advanced Metastatic Colorectal Cancer

Colorectal Cancer | Radiotherapy | Immunotherapy | Targeted Therapy

China
Peking University Cancer Hospital & Institute

Not yet recruiting

Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer (ERSS-EGC)

Gastric Cancer | Esophageal Cancer | Risk Stratification | Precision Screening | Sequential Screening

China
Shandong Cancer Hospital and Institute

Recruiting

MRI Guided SIB Radiotherapy in Neoadjuvant Therapy for Advanced Rectal Cancer

Rectal Cancer

China
Peking University Cancer Hospital & Institute

Not yet recruiting

Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

Collecting Duct Carcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe

Cancer

China
Peking University Cancer Hospital & Institute

Not yet recruiting

KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

HER2-positive Colorectal Cancer | HER2-positive Biliary Tract Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

The Value of MRI in Assessing the Status of Retroperitoneal Resection Margin in Colon Cancer

Colon Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy

Liver Metastasis Colon Cancer | Advanced Colorectal Carcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Shandong Cancer Hospital and Institute

Recruiting

Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.

Advanced Esophageal Squamous Cell Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma

Urothelial Carcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NeoIpower)

Non-Small Cell Lung Cancer

China
Shandong Cancer Hospital and Institute

Not yet recruiting

Patient Report Outcome and Oncological Safety -Oncoplastic and Conventional BCS Cohort

Breast Cancer Female | Patient Reported Outcome | Breast-conserving Surgery | Oncological Safety
Peking University Cancer Hospital & Institute

Not yet recruiting

cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC

HCC | Regorafenib | Transarterial Chemoembolization | Hepatic Arterial Infusion Chemotherapy
Peking University Cancer Hospital & Institute

Not yet recruiting

Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC

Non Small Cell Lung Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

PD-L1 Targeting Molecular Imaging of Solid Tumors

Gastrointestinal Tumors

China
Peking University Cancer Hospital & Institute

Not yet recruiting

Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma

Mucosal Melanoma | Neoadjuvant Treatment

China
Peking University Cancer Hospital & Institute

Recruiting

99mTc-MIRC208 SPECT/CT Imaging for HER2-Positive Cancer Patients

Cancer

China
Shandong Cancer Hospital and Institute

Not yet recruiting

A Phase II Clinical Study of SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in Extensive Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer
Peking University Cancer Hospital & Institute

Recruiting

The Molecular Imaging Research of F-18 Labeled DX600 PET Probe

Solid Tumor

China
Peking University Cancer Hospital & Institute

Recruiting

Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study

Mucosal Melanoma

China
Peking University Cancer Hospital & Institute

Recruiting

Induction Chemotherapy for MRF-negative, Moderate-risk, Resectable Middle and Low Rectal Cancer

Rectal Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for AGC

Laparoscopic Surgery | Gastric Cancer | Gastrectomy | Lymphadenectomy

China
Shandong Cancer Hospital and Institute

Not yet recruiting

Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

HER2-positive Breast Cancer
Shandong Cancer Hospital and Institute

Recruiting

Shandong Cancer Hospital Affiliated to Shandong University

Early-stage Breast Cancer | Breast Conserving Surgery

China
Peking University Cancer Hospital & Institute

Completed

Preliminary Study on Eye Features of Patients With Malignant Tumors

Cancer Patients | Feature Elongation

China
Shandong Cancer Hospital and Institute

Completed

Study of Epigallocatechin-3-gallate (EGCG) for Supportive and Symptomatic Management in Patients With Esophageal Cancer

Esophageal Obstruction

China
Peking University Cancer Hospital & Institute

Completed

The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

HCC

China
Peking University Cancer Hospital & Institute

Active, not recruiting

RSYR for Fatigue Reduction in Cancer Fatigue Caused by Chemotherapy (TCM)

Cancer-related Problem/Condition

China
Peking University Cancer Hospital & Institute

Completed

Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung Cancer

Lung Cancer Metastatic

China
Peking University Cancer Hospital & Institute

Completed

Different Radiation Dose With Concurrent Chemotherapy for Thoracic Esophageal Carcinoma

Esophageal Cancer

China
Peking University Cancer Hospital & Institute

Completed

Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment

Rectal Cancer

China
Peking University Cancer Hospital & Institute

Unknown

Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI

Magnetic Resonance Imaging | Positron-Emission Tomography

China
Shandong Cancer Hospital and Institute

Unknown

Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis

Breast Cancer | HER2-positive Breast Cancer

China
Peking University Cancer Hospital & Institute

Unknown

TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC (OXRI)

Hepatocellular Carcinoma | Transarterial Chemoembolization
Shandong Cancer Hospital and Institute

Unknown

A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma

Glioblastoma
Peking University Cancer Hospital & Institute

Unknown

Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma

Melanoma
Peking University Cancer Hospital & Institute

Unknown

Drug Sensitivity Screening for Gastrointestinal Cancer

Gastrointestinal Cancer Metastatic

China
Shandong Cancer Hospital and Institute

Terminated

A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC

Esophageal Neoplasms

China
Shandong Cancer Hospital and Institute

Unknown

Validation Studies of Biomarkers for Precision Radiation Oncology in Locally Advanced Solid Tumors

Advanced Cancer | Radiation Toxicity | Radiosensitivity

China
Shandong Cancer Hospital and Institute

Unknown

Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib

Recurrent Glioblastoma

China
Peking University Cancer Hospital & Institute

Unknown

PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma

Melanoma

China
Shandong Cancer Hospital and Institute

Unknown

Intraoperative Molecular Diagnosis of Sentinel Lymph Node In Breast Cancer Patients

Sentinel Lymph Node Biopsy

China
Peking University Cancer Hospital & Institute

Completed

RSYR for Fatigue Reduction in Cancer Survivors

Cancer-related Problem/Condition
Shandong Cancer Hospital and Institute

Unknown

Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC (CONSIST)

Carcinoma, Non-Small Cell Lung

China
Shandong Cancer Hospital and Institute

Unknown

Minimally Invasive Biopsy Predicting Breast pCR After NAC for Breast Cancer (MIBPBPCR)

Breast Cancer

China

Clinical Trials Sponsored by Jiangsu Cancer Institute & Hospital

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations